Bill Haney, Skyhawk
Genentech inks its latest discovery deal — this time turning to RNA upstart Skyhawk
Roche’s Genentech has just completed the latest in a string of discovery deals with a lineup of much, much smaller companies looking to do new things in drug development.
Right on the heels of the news of Sosei’s coup bringing Genentech on board as a partner for its GPCR platform, the prolific dealmakers at Skyhawk — run by Bill Haney — have just added the storied biotech subsidiary as its latest partner in the world of drugging RNA.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters